,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2013', 'fs': 'Feb 2013', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005Oum4UAC'}, 'Id': 'a0P2P000005Oum4UAC', 'Event_Date__c': '2013-02-01', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Feb 2013', 'Status_History__c': 'a132P000000AqI3QAK'}, 'change': None}]",Feb 2013,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2013', 'fs': 'Feb 2013', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005Oum5UAC'}, 'Id': 'a0P2P000005Oum5UAC', 'Event_Date__c': '2013-02-27', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Feb 2013', 'Status_History__c': 'a132P000000AqL7QAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-catsop-subcommittee-minutes-2013-03-22.pdf"" target=""_blank"">CaTSoP Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-catsop-subcommittee-minutes-2013-03-22.pdf"" target=""_blank"">CaTSoP Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Mar 2013', 'fs': 'Mar 2013', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 22 March 2013.', 'fs': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 22 March 2013.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005Oum7UAC'}, 'Id': 'a0P2P000005Oum7UAC', 'Event_Date__c': '2013-03-22', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 22 March 2013.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-catsop-subcommittee-minutes-2013-03-22.pdf"" target=""_blank"">CaTSoP Subcommittee minutes</a>', 'Outcome__c': 'High', 'Formatted_Date__c': 'Mar 2013', 'Status_History__c': 'a132P000000AqLuQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2013', 'fs': 'May 2013', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005Oum8UAC'}, 'Id': 'a0P2P000005Oum8UAC', 'Event_Date__c': '2013-05-01', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'May 2013', 'Status_History__c': 'a132P000000AqOTQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Recommended for funding with no priority', 'fs': 'Recommended for funding with no priority', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2013-05.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2013-05.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'May 2013', 'fs': 'May 2013', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 9 May 2013.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 9 May 2013.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005Oum9UAC'}, 'Id': 'a0P2P000005Oum9UAC', 'Event_Date__c': '2013-05-09', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 9 May 2013.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2013-05.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Recommended for funding with no priority', 'Formatted_Date__c': 'May 2013', 'Status_History__c': 'a132P000000AqP9QAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2013', 'fs': 'Jul 2013', 'change': None}, 'Event_Description': {'s': 'PHARMAC has put in place an exemption from HML for dexrazoxane. There is an exemption for the use of this agent in children who are enrolled in a Children&#39;s Oncology Group trial. Please note that as PHARMAC is providing an exemption, rather than a Schedule listing, the final decision on its use in this population will be a matter of discretion for each DHB.    With such an excemption in place, PHARMAC is not considering an HML listing at this time.', 'fs': 'PHARMAC has put in place an exemption from HML for dexrazoxane. There is an exemption for the use of this agent in children who are enrolled in a Children&#39;s Oncology Group trial. Please note that as PHARMAC is providing an exemption, rather than a Schedule listing, the final decision on its use in this population will be a matter of discretion for each DHB.    With such an excemption in place, PHARMAC is not considering an HML listing at this time.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005OumAUAS'}, 'Id': 'a0P2P000005OumAUAS', 'Event_Date__c': '2013-07-01', 'Event_Description__c': 'PHARMAC has put in place an exemption from HML for dexrazoxane. There is an exemption for the use of this agent in children who are enrolled in a Children&#39;s Oncology Group trial. Please note that as PHARMAC is providing an exemption, rather than a Schedule listing, the final decision on its use in this population will be a matter of discretion for each DHB.    With such an excemption in place, PHARMAC is not considering an HML listing at this time.', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jul 2013', 'Status_History__c': 'a132P000000AqRBQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Recommended for funding with no priority', 'fs': 'Recommended for funding with no priority', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2013-08.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2013-08.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2013', 'fs': 'Aug 2013', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 30 August 2013.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 30 August 2013.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005OumCUAS'}, 'Id': 'a0P2P000005OumCUAS', 'Event_Date__c': '2013-08-30', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 30 August 2013.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2013-08.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Recommended for funding with no priority', 'Formatted_Date__c': 'Aug 2013', 'Status_History__c': 'a132P000000AqSXQA0'}, 'change': None}, {'Summary': {'s': 'Recommended a small amendment to the exemption that is in place for dexrazoxane.', 'fs': 'Recommended a small amendment to the exemption that is in place for dexrazoxane.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'fs': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'change': None}, 'Outcome': {'s': 'Recommended alteration to access criteria', 'fs': 'Recommended alteration to access criteria', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-catsop-subcommittee-minutes-2013-09.pdf"" target=""_blank"">CaTSoP Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-catsop-subcommittee-minutes-2013-09.pdf"" target=""_blank"">CaTSoP Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Sep 2013', 'fs': 'Sep 2013', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 13 September 2013.', 'fs': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 13 September 2013.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005OumDUAS'}, 'Id': 'a0P2P000005OumDUAS', 'Event_Date__c': '2013-09-13', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 13 September 2013.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-catsop-subcommittee-minutes-2013-09.pdf"" target=""_blank"">CaTSoP Subcommittee minutes</a>', 'Outcome__c': 'Recommended alteration to access criteria', 'Summary__c': 'Recommended a small amendment to the exemption that is in place for dexrazoxane.', 'Formatted_Date__c': 'Sep 2013', 'PTAC_Comments__c': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'Status_History__c': 'a132P000000AqTHQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Recommended alteration to access criteria', 'fs': 'Recommended alteration to access criteria', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2014-02.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2014-02.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Feb 2014', 'fs': 'Feb 2014', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 13 February 2014.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 13 February 2014.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005OumEUAS'}, 'Id': 'a0P2P000005OumEUAS', 'Event_Date__c': '2014-02-13', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 13 February 2014.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2014-02.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Recommended alteration to access criteria', 'Formatted_Date__c': 'Feb 2014', 'Status_History__c': 'a132P000000AqbdQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-minutes-2017-14.pdf"" target=""_blank"">CaTSoP Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-minutes-2017-14.pdf"" target=""_blank"">CaTSoP Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Mar 2017', 'fs': 'Mar 2017', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 24 March 2017.', 'fs': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 24 March 2017.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005OumFUAS'}, 'Id': 'a0P2P000005OumFUAS', 'Event_Date__c': '2017-03-24', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 24 March 2017.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-minutes-2017-14.pdf"" target=""_blank"">CaTSoP Subcommittee minutes</a>', 'Outcome__c': 'High', 'Formatted_Date__c': 'Mar 2017', 'Status_History__c': 'a132P000000ArGYQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2017', 'fs': 'Nov 2017', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005OumGUAS'}, 'Id': 'a0P2P000005OumGUAS', 'Event_Date__c': '2017-11-24', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Nov 2017', 'Status_History__c': 'a132P000000ArNfQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Low', 'fs': 'Low', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-02.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-02.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Feb 2018', 'fs': 'Feb 2018', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 8 February 2018.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 8 February 2018.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005OumHUAS'}, 'Id': 'a0P2P000005OumHUAS', 'Event_Date__c': '2018-02-08', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 8 February 2018.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-02.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Low', 'Formatted_Date__c': 'Feb 2018', 'Status_History__c': 'a132P000000ArPuQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2018', 'fs': 'Feb 2018', 'change': None}, 'Event_Description': {'s': 'PHARMAC has created an exception to the HML for this use', 'fs': 'PHARMAC has created an exception to the HML for this use', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005OumIUAS'}, 'Id': 'a0P2P000005OumIUAS', 'Event_Date__c': '2018-02-09', 'Event_Description__c': 'PHARMAC has created an exception to the HML for this use', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Feb 2018', 'Status_History__c': 'a132P000000ArQ1QAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': '<h3 style=""text-align: justify;"">Dexrazoxane criteria </h3><p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in February 2018, PTAC recommended that dexrazoxane for cardioprotection in conjunction with anthracycline chemotherapy in children and young adults be funded with low priority subject to Special Authority criteria.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that at its March 2017 meeting CaTSoP had considered and recommended dexrazoxane be listed on the Schedule with medium priority but had not recommended access criteria; and in February 2018, PTAC considered the proposed Special Authority should be reviewed by the Cancer Treatments Subcommittee.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee recommended that dexrazoxane be funded for cardioprotection in conjunction with anthracycline chemotherapy in children and young adults subject to the following access criteria:</p><p style=""text-align: justify;"">\t<span style=""font-size: 10pt;"">Restricted</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">Initiation</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">Medical oncologist, paediatric oncologist, haematologist, paediatric haematologist</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">\xa0</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">Patient is to receive treatment with high dose anthracycline given with curative intent; and</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">Based on current treatment plan, patient’s cumulative lifetime dose of anthracycline will exceed 250mg/m2 doxorubicin equivalent or greater; and</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">Dexrazoxane to be administered only whilst on anthracycline treatment; and</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">Either:</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">4.1.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 10pt;"">Treatment to be used as a cardioprotectant for a child or young adult; or</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">4.2.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 10pt;"">Treatment to be used as a cardioprotectant for secondary malignancy.</span></p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the Adolescent and Young Adult (AYA) definition of child or young adult was patients aged 16-24 years, however considered that it was not appropriate to specify an age in the access criteria as patients receiving cumulative lifetime doses of anthracycline in excess of 250mg/m2 with curative intent could be older than that specified by the AYA definition. The Subcommittee considered it was not appropriate to exclude patients on the basis of age when the criteria for curative intent of high dose anthracycline would be met.</p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that recommended funding of dexrazoxane was not intended to include use in populations with advanced tumours for which anthracycline treatment was not administered with curative intent, such as for adult metastatic breast cancer patients, as the rationale for use of dexrazoxane was to prevent cardiac issue later in life for children and young adults. The Subcommittee considered there was no evidence for use of dexrazoxane in patients with pre-existing heart issues. </p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that while secondary malignancy where further anthracycline would be administered with curative intent exceeding the specified lifetime dose threshold was rare, it would be important to include these patients.</p>', 'fs': '<h3 style=""text-align: justify;"">Dexrazoxane criteria </h3><p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in February 2018, PTAC recommended that dexrazoxane for cardioprotection in conjunction with anthracycline chemotherapy in children and young adults be funded with low priority subject to Special Authority criteria.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that at its March 2017 meeting CaTSoP had considered and recommended dexrazoxane be listed on the Schedule with medium priority but had not recommended access criteria; and in February 2018, PTAC considered the proposed Special Authority should be reviewed by the Cancer Treatments Subcommittee.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee recommended that dexrazoxane be funded for cardioprotection in conjunction with anthracycline chemotherapy in children and young adults subject to the following access criteria:</p><p style=""text-align: justify;"">\t<span style=""font-size: 10pt;"">Restricted</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">Initiation</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">Medical oncologist, paediatric oncologist, haematologist, paediatric haematologist</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">\xa0</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">Patient is to receive treatment with high dose anthracycline given with curative intent; and</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">Based on current treatment plan, patient’s cumulative lifetime dose of anthracycline will exceed 250mg/m2 doxorubicin equivalent or greater; and</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">Dexrazoxane to be administered only whilst on anthracycline treatment; and</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">Either:</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">4.1.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 10pt;"">Treatment to be used as a cardioprotectant for a child or young adult; or</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">4.2.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 10pt;"">Treatment to be used as a cardioprotectant for secondary malignancy.</span></p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the Adolescent and Young Adult (AYA) definition of child or young adult was patients aged 16-24 years, however considered that it was not appropriate to specify an age in the access criteria as patients receiving cumulative lifetime doses of anthracycline in excess of 250mg/m2 with curative intent could be older than that specified by the AYA definition. The Subcommittee considered it was not appropriate to exclude patients on the basis of age when the criteria for curative intent of high dose anthracycline would be met.</p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that recommended funding of dexrazoxane was not intended to include use in populations with advanced tumours for which anthracycline treatment was not administered with curative intent, such as for adult metastatic breast cancer patients, as the rationale for use of dexrazoxane was to prevent cardiac issue later in life for children and young adults. The Subcommittee considered there was no evidence for use of dexrazoxane in patients with pre-existing heart issues. </p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that while secondary malignancy where further anthracycline would be administered with curative intent exceeding the specified lifetime dose threshold was rare, it would be important to include these patients.</p>', 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': 'These minutes have not yet been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'fs': 'These minutes have not yet been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': '<p><a href=""https://www.pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-record-2019-07.pdf"" target=""_blank"">CaTSoP Subcommittee Record</a></p>', 'fs': '<p><a href=""https://www.pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-record-2019-07.pdf"" target=""_blank"">CaTSoP Subcommittee Record</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Oct 2019', 'fs': 'Oct 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 5 July 2019.', 'fs': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 5 July 2019.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005OumJUAS'}, 'Id': 'a0P2P000005OumJUAS', 'Event_Date__c': '2019-10-29', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 5 July 2019.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<p><a href=""https://www.pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-record-2019-07.pdf"" target=""_blank"">CaTSoP Subcommittee Record</a></p>', 'Outcome__c': 'No Formal Recommendation', 'Formatted_Date__c': 'Oct 2019', 'Published_Discussion__c': '<h3 style=""text-align: justify;"">Dexrazoxane criteria </h3><p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in February 2018, PTAC recommended that dexrazoxane for cardioprotection in conjunction with anthracycline chemotherapy in children and young adults be funded with low priority subject to Special Authority criteria.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that at its March 2017 meeting CaTSoP had considered and recommended dexrazoxane be listed on the Schedule with medium priority but had not recommended access criteria; and in February 2018, PTAC considered the proposed Special Authority should be reviewed by the Cancer Treatments Subcommittee.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee recommended that dexrazoxane be funded for cardioprotection in conjunction with anthracycline chemotherapy in children and young adults subject to the following access criteria:</p><p style=""text-align: justify;"">\t<span style=""font-size: 10pt;"">Restricted</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">Initiation</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">Medical oncologist, paediatric oncologist, haematologist, paediatric haematologist</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">\xa0</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">Patient is to receive treatment with high dose anthracycline given with curative intent; and</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">Based on current treatment plan, patient’s cumulative lifetime dose of anthracycline will exceed 250mg/m2 doxorubicin equivalent or greater; and</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">Dexrazoxane to be administered only whilst on anthracycline treatment; and</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">Either:</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">4.1.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 10pt;"">Treatment to be used as a cardioprotectant for a child or young adult; or</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">4.2.</span><span style=""font-size: 7pt;"">\xa0\xa0</span><span style=""font-size: 10pt;"">Treatment to be used as a cardioprotectant for secondary malignancy.</span></p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the Adolescent and Young Adult (AYA) definition of child or young adult was patients aged 16-24 years, however considered that it was not appropriate to specify an age in the access criteria as patients receiving cumulative lifetime doses of anthracycline in excess of 250mg/m2 with curative intent could be older than that specified by the AYA definition. The Subcommittee considered it was not appropriate to exclude patients on the basis of age when the criteria for curative intent of high dose anthracycline would be met.</p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that recommended funding of dexrazoxane was not intended to include use in populations with advanced tumours for which anthracycline treatment was not administered with curative intent, such as for adult metastatic breast cancer patients, as the rationale for use of dexrazoxane was to prevent cardiac issue later in life for children and young adults. The Subcommittee considered there was no evidence for use of dexrazoxane in patients with pre-existing heart issues. </p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that while secondary malignancy where further anthracycline would be administered with curative intent exceeding the specified lifetime dose threshold was rare, it would be important to include these patients.</p>', 'PTAC_Comments__c': 'These minutes have not yet been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'Status_History__c': 'a132P000000B5i1QAC'}, 'change': None}]",Feb 2013,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2013', 'fs': 'Mar 2013', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005Oum6UAC'}, 'Id': 'a0P2P000005Oum6UAC', 'Event_Date__c': '2013-03-01', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Mar 2013', 'Status_History__c': 'a132P000000AqLRQA0'}, 'change': None}]",Mar 2013,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,,,False,False
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,,,False,False
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,,,False,False
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': '<p><span style=""color: rgb(62, 62, 60);"">Funding effective July 2013.</span></p>', 'fs': '<p><span style=""color: rgb(62, 62, 60);"">Funding effective July 2013.</span></p>', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2013', 'fs': 'Jul 2013', 'change': None}, 'Event_Description': {'s': 'The funding application has been approved.', 'fs': 'The funding application has been approved.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000005OumBUAS'}, 'Id': 'a0P2P000005OumBUAS', 'Event_Date__c': '2013-07-31', 'Event_Description__c': 'The funding application has been approved.', 'Stage__c': 'Decision', 'Summary__c': '<p><span style=""color: rgb(62, 62, 60);"">Funding effective July 2013.</span></p>', 'Formatted_Date__c': 'Jul 2013', 'Status_History__c': 'a132P000000CSNzQAO'}, 'change': None}]",Jul 2013,False,True
